Payment overview · 2025
General Payments
$1,537.86
82 reported records · 21 companies
Healthcare provider profile · identity verified
Ben Lee, D.O
Allopathic & Osteopathic Physicians|Internal Medicine · BRIGHTON, MI · NPI 1376884833
Verified facts
What the public records show
CMS Open Payments records show Ben Lee, D.O received $1,537.86 in general payments during 2025 across 82 reported records.
Novo Nordisk Inc accounted for 13.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 197 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 178 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $203.10 | 13.2% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $181.17 | 11.8% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $170.44 | 11.1% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $155.30 | 10.1% | 11 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $125.07 | 8.1% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $82.76 | 5.4% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $76.78 | 5.0% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $75.32 | 4.9% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $70.08 | 4.6% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $68.25 | 4.4% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $63.31 | 4.1% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $62.72 | 4.1% | 3 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $31.44 | 2.0% | 2 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.91 | 2.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $30.52 | 2.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $27.58 | 1.8% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $18.07 | 1.2% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $17.50 | 1.1% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $16.34 | 1.1% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $16.10 | 1.1% | 1 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $15.10 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,537.86 | 82 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $140.44 | 6 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $125.07 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $118.03 | 8 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $118.03 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $113.92 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $113.75 | 6 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $76.78 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $70.08 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $68.25 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $68.11 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $67.03 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $62.72 | 3 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $61.73 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $58.73 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $58.73 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $55.59 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $46.03 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $44.72 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $44.72 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $39.06 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $37.27 | 3 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $31.44 | 2 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $30.91 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $30.52 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $30.00 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $27.58 | 1 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $21.03 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.73 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.73 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.73 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $18.59 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $18.07 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $17.50 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.53 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $16.34 | 1 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $15.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 178 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 56 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 124 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 96 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 197 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 123 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
56 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
56 | 19 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
124 | 34 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
123 | 35 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
124 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
96 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
56 | 14 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
197 | 52 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
178 | 62 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
20 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 624 | 207 |
| Levothyroxine Sodium | Levothyroxine Sodium | 623 | 194 |
| Atorvastatin Calcium | Atorvastatin Calcium | 621 | 219 |
| Amlodipine Besylate | Amlodipine Besylate | 495 | 172 |
| Gabapentin | Gabapentin | 428 | 122 |
| Omeprazole | Omeprazole | 412 | 133 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 408 | 128 |
| Metoprolol Succinate | Metoprolol Succinate | 402 | 125 |
| Lisinopril | Lisinopril | 396 | 146 |
| Tamsulosin Hcl | Tamsulosin Hcl | 346 | 125 |
| Pantoprazole Sodium | Pantoprazole Sodium | 315 | 113 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 302 | 88 |
| Metformin Hcl | Metformin Hcl | 301 | 99 |
| Prednisone | Prednisone | 258 | 169 |
| Meloxicam | Meloxicam | 233 | 107 |
| Pravastatin Sodium | Pravastatin Sodium | 225 | 73 |
| Hydrochlorothiazide | Hydrochlorothiazide | 213 | 68 |
| Furosemide | Furosemide | 212 | 81 |
| Simvastatin | Simvastatin | 210 | 74 |
| Alprazolam | Alprazolam | 206 | 57 |
| Tramadol Hcl | Tramadol Hcl | 206 | 57 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 199 | 67 |
| Ozempic | Semaglutide | 197 | 52 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 186 | 88 |
| Metformin Hcl Er | Metformin Hcl | 185 | 66 |
| Metoprolol Tartrate | Metoprolol Tartrate | 180 | 64 |
| Eliquis | Apixaban | 178 | 62 |
| Trazodone Hcl | Trazodone Hcl | 173 | 52 |
| Clopidogrel | Clopidogrel Bisulfate | 171 | 58 |
| Carvedilol | Carvedilol | 167 | 54 |
| Montelukast Sodium | Montelukast Sodium | 158 | 55 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 156 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 141 | 49 |
| Quetiapine Fumarate | Quetiapine Fumarate | 133 | 42 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 124 | 53 |
| Jardiance | Empagliflozin | 124 | 34 |
| Sertraline Hcl | Sertraline Hcl | 124 | 40 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 123 | 35 |
| Citalopram Hbr | Citalopram Hydrobromide | 118 | 33 |
| Potassium Chloride | Potassium Chloride | 118 | 43 |
| Baclofen | Baclofen | 115 | 63 |
| Xarelto | Rivaroxaban | 110 | 33 |
| Clonazepam | Clonazepam | 103 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 100 | 23 |
| Mounjaro | Tirzepatide | 96 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 89 | 35 |
| Azithromycin | Azithromycin | 86 | 68 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 86 | 27 |
| Cephalexin | Cephalexin | 82 | 65 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 82 | 12 |
| Finasteride | Finasteride | 81 | 28 |
| Allopurinol | Allopurinol | 80 | 30 |
| Warfarin Sodium | Warfarin Sodium | 80 | 19 |
| Buspirone Hcl | Buspirone Hcl | 79 | 29 |
| Pregabalin | Pregabalin | 76 | 28 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 73 | 21 |
| Ezetimibe | Ezetimibe | 72 | 30 |
| Ibuprofen | Ibuprofen | 71 | 28 |
| Bupropion Xl | Bupropion Hcl | 70 | 32 |
| Paroxetine Hcl | Paroxetine Hcl | 70 | 23 |
| Methylprednisolone | Methylprednisolone | 69 | 53 |
| Mirtazapine | Mirtazapine | 69 | 28 |
| Alendronate Sodium | Alendronate Sodium | 67 | 29 |
| Diazepam | Diazepam | 63 | 27 |
| Testosterone Cypionate | Testosterone Cypionate | 62 | 22 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 60 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 60 | 24 |
| Farxiga | Dapagliflozin Propanediol | 56 | 19 |
| Synthroid | Levothyroxine Sodium | 56 | 16 |
| Trulicity | Dulaglutide | 56 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 55 | 44 |
| Glimepiride | Glimepiride | 54 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 52 | 19 |
| Ondansetron Odt | Ondansetron | 51 | 17 |
| Cefuroxime | Cefuroxime Axetil | 50 | 32 |
| Diclofenac Sodium | Diclofenac Sodium | 50 | 25 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 49 | 18 |
| Celecoxib | Celecoxib | 49 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 49 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 45 | 14 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 44 | 14 |
| Famotidine | Famotidine | 44 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 43 | 24 |
| Topiramate | Topiramate | 43 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 41 | 20 |
| Meclizine Hcl | Meclizine Hcl | 41 | 15 |
| Lovastatin | Lovastatin | 40 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 39 | 15 |
| Aripiprazole | Aripiprazole | 38 | 12 |
| Nitroglycerin | Nitroglycerin | 37 | 29 |
| Lorazepam | Lorazepam | 36 | 11 |
| Spironolactone | Spironolactone | 36 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 36 | 24 |
| Januvia | Sitagliptin Phosphate | 35 | 13 |
| Enalapril Maleate | Enalapril Maleate | 34 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Valsartan | Valsartan | 34 | 12 |
| Amoxicillin | Amoxicillin | 32 | 19 |
| Bumetanide | Bumetanide | 32 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | 15 |
| Lidocaine | Lidocaine | 32 | 12 |
| Nifedipine Er | Nifedipine | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 16 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 30 | 15 |
| Gemfibrozil | Gemfibrozil | 29 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 29 | suppressed |
| Entresto | Sacubitril/Valsartan | 28 | suppressed |
| Fluconazole | Fluconazole | 28 | 15 |
| Naproxen | Naproxen | 27 | 15 |
| Atenolol | Atenolol | 26 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 26 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 25 | 19 |
| Venlafaxine Hcl | Venlafaxine Hcl | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 18 |
| Metoclopramide Hcl | Metoclopramide Hcl | 24 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Folic Acid | Folic Acid | 23 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 20 |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 22 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | 13 |
| Armodafinil | Armodafinil | 21 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | 11 |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Cilostazol | Cilostazol | 20 | suppressed |
| Colchicine | Colchicine | 20 | 12 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 20 | suppressed |
| Lactulose | Lactulose | 20 | suppressed |
| Metronidazole | Metronidazole | 20 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | 16 |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Nystatin | Nystatin | 19 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 17 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 16 | 15 |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 15 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 14 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Percocet | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Progesterone | Progesterone, Micronized | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Buprenorphine | Buprenorphine | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | 11 |
| Glipizide Er | Glipizide | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,537.86 · 82 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, COMIRNATY, CeQur Simplicity, Cologuard Collection Kit, ELIQUIS, EVENITY, FANAPT, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, JASCAYD, JATENZO, LEQVIO, LUMRYZ, MOUNJARO, NURTEC ODT, NUZYRA, OFEV, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Veozah, Wegovy, ZAVZPRET, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error